Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Trop‑2/TACSTD2 is a single-pass type I membrane glycoprotein receptor that acts both as a marker for carcinoma cells and an active participant driving tumorigenesis through calcium-mediated signal transduction pathways. Its unique structure-function relationships make it both diagnostically valuable and therapeutically actionable across multiple human cancers.
Antibody-drug conjugates target TROP2 expressing cells, delivering a cytotoxic payload upon internalization.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor-associated calcium signal transducer 2 (TROP2).